TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent from patient or legal representative.~2. Male or female, aged ≥ 18 years;~3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source;~4. Signs of respiratory failure requiring oxygen therapy~5. Hospitalized for up to 36h with non-invasive ventilation~6. Negative result for pregnancy test (if applicable).~Exclusion Criteria:~1. Participating in another RCT in the past 12 months;~2. Known allergy to nitazoxanide~3. Severely reduced LV function;~4. Severely reduced renal function;~5. Pregnancy or breast feeding;~6. Use of hydroxychloroquine and/or azithromycin in the past 15 days;~7. Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nitazoxanide (Type: EXPERIMENTAL): Patients will receive nitazoxanide 600 mg BID for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo BID for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All Patients older than 18 years scheduled for coronary angiography and/or PCI will be enrolled. \[Patients should be CK-MB negative (to avoid CK washout with revascularization) and also cTnI/T negative whereas other high-risk features will not lead to patient exclusion.~2. All consecutive patients with stable or unstable troponin and CK-MB negative coronary artery disease showing aspirin and or clopidogrel resistance (ACR) will be enrolled. These include:~   * Patients with clinical indication to undergo angiography for possible revascularisation.~  * Patients with ACR in whom catheter-based coronary intervention is planned based on previous angiogram.~Exclusion Criteria:~1. Patients who can not give informed consent or have a life expectancy of \< 1 year~2. Evolving or Ongoing myocardial infarction (MI) (Persistence of or developing Q wave or ST segment elevation at ECG with or without typical chest pain or typical rapid rise and fall CK-MB or new LBBB) or patients in whom the treating physician intends to use a Gp IIB/IIIa inhibitors.~3. Administration of any GP IIb/IIIa receptor antagonist, anticoagulation, or lytic therapy in the previous 30 days~4. Serum creatinine more than 2.5 mg/dl (221 micromol/L)~5. Ongoing bleeding or bleeding diathesis or contraindication for anticoagulation or increase bleeding risk or history of bleeding in the last 1 year~6. Previous stroke or TIA or any intracranial pathology in the last six months~7. Major surgery or trauma within the previous six weeks~8. Platelet count \< 100.000 per cubic mm or HCT ,33% or Hb \< 11 gm/dL~9. Subjects who received low-molecular-weight heparin within the 24 hours prior to randomization~10. Subjects with an allergy or intolerance to aspirin, heparin, clopidogrel, or tirofiban~11. Patients with severe hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg) or in cardiogenic shock (SBP 80 mm Hg or below for \> 30 minutes) or requiring IABP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
- 2 (Type: PLACEBO_COMPARATOR): Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection~* In the judgement of the investigator, it is appropriate to initiate ARV therapy based on the patients medical condition and taking into account applicable guidelines for the treatment of HIV-1 infection~* Patient has access to an investigator-selected ARV regimen post-study in accordance with applicable guidelines for the treatment of HIV-1 infection~* HIV-1 plasma viral load at screening \>= 5000 HIV-1 RNA (copies/ml)~* Predicted phenotypic sensitivity to the currently approved NNRTIs and to the N(t)RTIs in their background regimen at screening~Exclusion Criteria:~* Any previous treatment with a therapeutic HIV vaccine or use of ARVs, including use of NVP for the prevention of vertical HIV transmission~* The presence of at least one of the mutations that are specific indicators of transmitted (or primary) drug resistance~* Known infection with HIV-2 or with HIV-1 group O~* Category C AIDS defining illness, except stable Kaposi's Sarcoma, wasting syndrome if not progressive~* Pneumocystis jiroveci/carinii Pneumonia (PCP) that is considered not cured~* Specific grade 3 or 4 laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- etravirine (Type: EXPERIMENTAL): etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
- efavirenz (Type: ACTIVE_COMPARATOR): efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Autism diagnostic observation schedule (ADOS) score of ≥ 7~* Diagnosis of autism spectrum disorder by Diagnostic and Statistical Manual, 5th edition (DSM-V)~* Stable treatment and diet regimen for ≥ 2 months~* Resident of San Diego region~Exclusion Criteria:~* Any prescription medications~* Hospitalization within the previous 2 months~* Active medical problem such as seizures, heart, liver, kidney, or adrenal disease~* Planning to start a new drug, diet, or behavioral intervention during the study~* Weight under the 5th percentile for age~* Unable to tolerate venipuncture, urine collection, or an indwelling intravenous catheter for 3-4 hours~* Plasma creatinine ≥ 1.4 mg/dl~* Liver function alanine amino transferase (ALT) or aspartate amino transferase (AST) ≥ 1.5-fold above the upper limit of normal~* Known intolerance to suramin or other antipurinergic drugs~* Unable to perform or cooperate with study requirements

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Suramin (Type: ACTIVE_COMPARATOR): 20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
- Saline (Type: PLACEBO_COMPARATOR): 50 ml of saline by intravenous infusion over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Cohort of Children With HIV Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center~* Children who fulfil criteria to start HAART according to the ATC program~* Children who are switched to second regimen or salvage therapy~* Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)~* Children with HIV infection who are not on antiretroviral therapy~* Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form~Exclusion Criteria:~* Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Long-term pediatric cohort (Type: None): Long-term follow-up cohort since 2003

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* hemodialysis or peritoneal dialysis, with same mode of dialysis for \>=3 months before and throughout screening period;~* continuous maintenance epoetin alfa or beta therapy with the same dosing interval during the previous 2 months.~Exclusion Criteria:~* transfusion of red blood cells during previous 2 months;~* poorly controlled hypertension requiring interruption of epoetin alfa or beta treatment in past 6 months;~* significant acute or chronic bleeding such as overt gastrointestinal bleeding;~* hemolysis;~* folic acid and vitamin B12 deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (C.E.R.A.), 1x/4weeks (Type: EXPERIMENTAL): Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator \[C.E.R.A\]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of\<8000, 8000-16000, or \>16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Titrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients older than 8 years and less than 50 years~* patients who consult emergency department for sever pain after an immediately trauma~Exclusion Criteria:~* Glasgow coma scale \<14~* inability to cooperate~* hypotension with systolic blood pressure\< 90mmhg~* bradypnea\<12cpm~* SAO2\<90%~* polytrauma~* nasal trauma~* rhinitis~* nasal obstruction~* allergy to opioids

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- IV titrated morphine (Type: PLACEBO_COMPARATOR): patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS \> 50%, 30 minutes after the beginning of the protocol.
- Low dose nebulised morphine (Type: EXPERIMENTAL): patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo
- High dose nebulised morphine (Type: EXPERIMENTAL): patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Opening Doors to Early Intervention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child is \<30 months old at time of enrollment~* Child was born \>35 weeks estimated gestational age~* Parent-child dyad reside in Philadelphia and present at a Children's Hospital of Philadelphia (CHOP) primary care practice located in Philadelphia~* Parents are English or Spanish speaking~* Child has recently been referred to the Philadelphia Infant Toddler Early Intervention Program in Philadelphia County~Exclusion Criteria:~* Child moves outside of Philadelphia County~* Child has received EI services in the past 2 weeks~* Child has congenital anomalies, genetic syndromes, or human immunodeficiency virus (HIV) that place them at risk of developmental delays

- Gender: ALL
- Minimum Age: None
- Maximum Age: 29 Months
- Healthy Volunteers: f

Study Arms:
- Usual Care (Control) (Type: NO_INTERVENTION): Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
- Family Navigator (Intervention) (Type: EXPERIMENTAL): Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with the second and subsequent attack of recurrent pericarditis,~* Age≥ 18 years,~* Informed consent.~Exclusion Criteria:~* Suspected neoplastic, tuberculous, or purulent etiology,~* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality,~* serum creatinine\>2.5 mg/dl,~* Serum CK over the upper limit of normality or Known myopathy,~* Known gastrointestinal or blood disease,~* Pregnant or lactating women or women not protected by a contraception method,~* Known hypersensibility to colchicine,~* Treatment with colchicine at the enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colchicine (Type: EXPERIMENTAL): Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tailored Therapy for Helicobacter Pylori Rescue Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-ulcer functional dyspepsia or scarred peptic ulcer disease~* Previous failures of H. pylori eradication therapy and need rescue therapy~* Ability and willingness to participate in the study and to sign and give informed consent~* Confirmed H. pylori infection~Exclusion Criteria:~* Less than 18 years old~* With previous gastric surgery~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs~* Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tailored Therapy (Type: EXPERIMENTAL): After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women identified at antenatal clinics after from 34 weeks gestation and who are antiretroviral drug naive.~* Mothers with a documented positive HIV Rapid test confirmed by a detectable HI V-1 RNA PCR (viral load).~* Mother to have a screening viral load of \> 2000 RNA copies/mL.~Exclusion Criteria:~* Mothers who, in the opinion of the investigator ,cannot be relied on to return with their infants for postnatal visits.~* Mothers who have received any antiretroviral drugs previously.~* Clinical suspicion of intra-uterine foetal death~* Unwillingness or inability to reasonably comply with the protocol requirements.~* Use of any other investigational product during the pregnancy and for the dura tion of the study period.~* Patients with a recent history of pancreatitis or peripheral neuropathy.~* Patients with renal failure requiring dialysis.~* Patients with evidence of hepatic dysfunction as measured by total bilirubin \> 2.5 times ULN or AST/ALT \> 5 times ULN at the screening visit.~* Patients with any one of the following additional laboratory abnormalities at screening : Haemoglobin concentration \< 7.5 g/dl. Neutrophil count \< 750 cells/mm3. Platelet count \< 75,000 cells/mm3. Serum amylase \> 2 x ULN.~* recent history ( during the pregnancy) of drug abuse or alcoholism.~* Mothers who will undergo elective caesarean section.~* If known prior to delivery, mothers with foetuses with anomalies incompatible with life.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).~* Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.~* Patients may not have any history of brain and/or leptomeningeal metastases.~* Patients may not have Grade 2 or worse neuropathy at the time of study entry.~* Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete